# Interlace Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/interlace-medical

- Industry: Medical Devices & Equipment
- Headquarters: Framingham, US
- Website: www.interlacemedical.com
- Total disclosed funding: $31M
- Latest round: Series C (Jun 10, 2009)
- Investors on record: 6

## About

Interlace Medical, Inc. focuses on developing innovative medical devices that enhance healthcare outcomes through advanced technology and efficient surgical solutions.Founded in 2006, Interlace Medical, Inc. is headquartered in Framingham, US, and specializes in creating medical devices for surgical procedures. In January 2011, the company was acquired by Hologic, Inc. for USD 125 mn, marking a significant transition in its operational strategy. The company has completed a total of 5 deals since inception, with its most recent deal occurring in January 2011.Interlace Medical, Inc. delivers a comprehensive suite of innovative surgical devices designed to improve operational efficiency and patient outcomes in healthcare. Their product offerings address specific surgical challenges, enabling healthcare professionals to enhance the precision and effectiveness of procedures. These solutions, developed over recent years, have gained traction in North America and Europe, primarily serving hospitals and surgical centers.Interlace Medical, Inc. operates on a revenue model that combines direct sales to healthcare providers and strategic partnerships with medical distributors. The pricing strategy for their flagship products aligns with industry standards, ensuring accessibility for a diverse range of healthcare facilities, from large hospitals to smaller surgical centers.Following its acquisition by Hologic, Inc. in January 2011 for USD 125 mn, Interlace Medical, Inc. is focused on expanding its product line with new surgical devices aimed at improving healthcare efficiencies. The company plans to tap into emerging markets in Asia Pacific and Latin America by 2023, utilizing resources from its recent funding to establish partnerships and enhance distribution networks in these regions. Future product launches are aimed at addressing evolving surgical needs as the company seeks to strengthen its market presence.

## Funding rounds

- Series C, Jun 10, 2009, $21M — Baird Capital Partners, Spray Venture Partners, HLM Venture Partners, Aperture Venture Partners, New Leaf Venture Partners, Tekla Capital Management
- Series B, Sep 3, 2008, $7M — Spray Venture Partners, New Leaf Venture Partners
- Series B, Apr 24, 2007, $3M — Spray Venture Partners, New Leaf Venture Partners

## Investors

- Spray Venture Partners (https://capitalatlas.ai/funds/spray-venture-partners) — Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series C
- HLM Venture Partners (https://capitalatlas.ai/funds/hlm-venture-partners) — Series C
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C